Cytori Therapeutics Inc Stock Nasdaq
Stocks
US23283K1051
Biotechnology & Medical Research
| Market Cap | 33.38M 28.77M 26.48M 24.84M 46.66M 3.15B 47.13M 313M 122M 1.55B 125M 123M 5.35B | P/E Ratio 2026 * |
-1.24x | P/E Ratio 2027 * | -2.03x |
|---|---|---|---|---|---|
| Enterprise Value | 33.38M 28.77M 26.48M 24.84M 46.66M 3.15B 47.13M 313M 122M 1.55B 125M 123M 5.35B | EV / Sales 2026 * |
5.3x | EV / Sales 2027 * | 1.74x |
| Free-Float |
98.37% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Cytori Therapeutics Inc
| 1 day | -1.85% |
| Manager | Title | Age | Since |
|---|---|---|---|
Marc Hedrick
CEO | Chief Executive Officer | 64 | 2014-04-01 |
Andrew Sims
DFI | Director of Finance/CFO | 52 | 2020-02-05 |
Daniel Ortega
CTO | Chief Tech/Sci/R&D Officer | - | 2025-10-20 |
| Director | Title | Age | Since |
|---|---|---|---|
Marc Hedrick
BRD | Director/Board Member | 64 | 2002-09-30 |
Richard Hawkins
CHM | Chairman | 77 | 2018-01-24 |
| Director/Board Member | 66 | 2019-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.85% | -29.07% | - | - | 33.38M | |
| -0.24% | -0.26% | -12.87% | -12.97% | 43.58B | |
| -3.30% | +3.90% | +290.70% | +531.11% | 34.03B | |
| -0.15% | -4.48% | +11.71% | -17.64% | 29.77B | |
| -0.49% | -0.89% | +0.52% | +32.76% | 29.82B | |
| -0.29% | +9.47% | +13.95% | +21.93% | 25.42B | |
| +2.66% | +7.09% | - | - | 13.87B | |
| -1.53% | -1.65% | +52.52% | +106.95% | 13.35B | |
| -0.76% | -3.20% | +2.71% | +2.28% | 12.85B | |
| -1.62% | -2.70% | +105.92% | +76.90% | 12.22B | |
| Average | -0.72% | +2.03% | +58.14% | +92.66% | 23.88B | |
| Weighted average by Cap. | -0.70% | +2.02% | +60.09% | +104.02% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 6.3M 5.43M 4.99M 4.68M 8.8M 595M 8.89M 59.03M 23.06M 291M 23.62M 23.12M 1.01B | 19.14M 16.5M 15.18M 14.24M 26.76M 1.81B 27.02M 179M 70.12M 886M 71.83M 70.31M 3.07B |
| Net income | -26.8M -23.1M -21.26M -19.94M -37.46M -2.53B -37.84M -251M -98.17M -1.24B -101M -98.44M -4.29B | -18.45M -15.91M -14.64M -13.73M -25.8M -1.74B -26.05M -173M -67.6M -854M -69.26M -67.79M -2.96B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
